William Blair Upgrades ResMed (RMD) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
ResMed (RMD) PT Lifted to $57 on Solid Q1
October 24, 2014 11:23 AM EDTPiper Jaffray analyst David Clair reiterated an Overweight rating and boosted his price target on ResMed (NYSE: RMD) price target of $57.00 (from $55.00) following solid Q1 results.
Clair commented, "ResMed reported 1Q15 revenue of $380.4M, above consensus' $374.8M and our $373.3M... More
ResMed (RMD) Reports In-Line Q1 EPS
October 23, 2014 4:20 PM EDTResMed (NYSE: RMD) reported Q1 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $380.4 million versus the consensus estimate of $375 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More